Last edition
News about "Zenas BioPharma signs USD 2 billion licensing deal"
Zenas BioPharma Signs USD 2 Billion Licensing Deal with InnoCare for Autoimmune Drugs
Zenas BioPharma has entered into a licensing agreement with China’s InnoCare Pharma worth up to USD 2 billion to develop and commercialise three autoimmune drug candidates, including a late-stage treatment for multiple sclerosis.
Zenas BioPharma Signs USD 2 Billion Licensing Deal | 09/10/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members